| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
ADC Control Human IgG1-SN-38 has no specific target. The antibody portion is a non-binding human IgG1 kappa isotype control, which does not recognize any particular antigen. Its purpose is to serve as a control in ADC experiments to assess the non-specific toxicity of the SN-38 payload and the effect of the linker. Any cytotoxic effect observed with this control ADC is attributed to non-specific uptake of the conjugate by cells (e.g., via pinocytosis or Fc receptor-mediated endocytosis), not target-specific binding. Therefore, it helps to distinguish target-dependent from target-independent effects.
|
|---|---|
| ln Vitro |
In vitro, the ADC Control Human IgG1-SN-38 is used in cell viability assays to assess non-specific toxicity. It is tested alongside a target-specific ADC on target-positive and target-negative cells. Any reduction in cell viability induced by the control ADC is considered non-specific toxicity. The compound is a standard quality control reagent for ADC development. In the search results, no specific IC50 values were provided for this control ADC, as its activity is expected to be minimal or moderate compared to a targeted ADC.
|
| ln Vivo |
As an isotype control, ADC Control Human IgG1-SN-38 is used in vivo in xenograft models to control for the effects of the nonspecific antibody. It is administered as a comparison to the therapeutic ADC to determine if the observed antitumor activity is due to specific targeting or simply to non-specific uptake of the conjugate. It can also be used to evaluate the systemic toxicity of the linker-payload. The body weight loss and changes in clinical chemistry parameters caused by the control ADC help to define the therapeutic window of the targeted ADC.
|
| Enzyme Assay |
The ADC is not used in cell-free assays. Its binding to cells is assessed by flow cytometry on target-positive and target-negative cells. The cells are incubated with the ADC (1-10 ug/mL) for 30-60 minutes at 4degC. After washing, bound antibody is detected with a fluorescently labeled anti-human IgG secondary antibody. The mean fluorescence intensity (MFI) is measured. The control ADC should not show higher binding than the isotype control antibody alone. Its purity, aggregation, and drug-to-antibody ratio (DAR) are characterized by HPLC-SEC and HIC-HPLC.
|
| Cell Assay |
For in vitro cell viability assays, target-positive and target-negative cells are seeded in 96-well plates (5,000-10,000 cells/well). After 24 hours, the cells are treated with varying concentrations of the ADC Control Human IgG1-SN-38 (0.01-1000 nM) or a targeted ADC for 96-120 hours. Cell viability is measured using an MTT or CellTiter-Glo assay. The EC50 for the control ADC is typically significantly higher than that of the targeted ADC on target-positive cells. The data helps to determine the selectivity index of the targeted ADC.
|
| Animal Protocol |
In a typical xenograft study, female BALB/c nude mice (6-8 weeks old) are subcutaneously injected with target-positive cancer cells (e.g., 5×10⁶ cells). When tumors reach an average volume of 150 mm3, the mice are randomized into groups (n=8-10). ADC Control Human IgG1-SN-38 is administered intravenously (IV) at a dose of 10 mg/kg (equivalent to the therapeutic ADC) once weekly for 2-4 weeks. The control group may also receive the unconjugated isotype antibody or saline. Tumor volume is measured twice weekly, and body weight is monitored for toxicity. The control ADC is used to determine the degree of target-independent antitumor activity.
|
| ADME/Pharmacokinetics |
As an ADC, ADC Control Human IgG1-SN-38 is administered intravenously. Its pharmacokinetic properties are largely determined by the antibody and are expected to be similar to those of the therapeutic ADC. The half-life of a human IgG1 in mice is typically 5-15 days. However, the conjugate may be cleared more rapidly due to the hydrophobic payload. The drug-to-antibody ratio (DAR) is an important quality attribute affecting PK. The search results did not provide specific PK data for this control ADC.
|
| Toxicity/Toxicokinetics |
The toxicity of the ADC Control Human IgG1-SN-38 is primarily due to the SN-38 payload. As an isotype control, it does not have target-specific uptake; however, it can still be taken up by cells non-specifically, leading to systemic toxicity. In vivo, the maximum tolerated dose (MTD) for this conjugate may be similar to that of the targeted ADC. The control ADC is used to distinguish between target-specific and non-specific toxicities. Standard safety precautions for handling cytotoxic ADCs should be followed.
|
| Additional Infomation |
ADC Control Human IgG1-SN-38 is a research-grade isotype control for antibody-drug conjugates (ADCs) using the SN-38 payload. It is an essential tool for ADC development, enabling researchers to validate the specificity and therapeutic window of their targeted ADCs. It is not an FDA-approved drug and is for research use only.
|
| Appearance |
Typically exists as solids at room temperature
|
|---|---|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
